2018 Clinical Trials DEA Patients 
NORML
JANUARY 17, 2019
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. A similar version of this bill was passed in the House Judiciary Committee in 2018 yet was not taken up by the full chamber.
Canna Law Blog
MAY 7, 2020
What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi. for various studies, including FDA-approved clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.
Cannabis Law Report
MAY 31, 2022
The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.
Cannabis Law Report
JULY 9, 2021
Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
MedicalJane
JUNE 29, 2018
On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. branch of Aphria, Inc.,
Expert insights. Personalized for you.
229 
Let's personalize your content